Brief Description

ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.
IC50 value: 3.5 nM
Target: ALK
in vitro: ASP3026 shows more selective ALK inhibition in a Tyr-kinase panel than PF02341066. ASP3026 inhibits the growth of NCI-H2228, a human NSCLC tumor cell line endogenously expressing EML4-ALK variant 3, with an IC50 value of 64.8 nM [1]. in vivo: ASP3026, administered to mice bearing subcutaneous NCI-H2228 tumor xenografts as twice daily oral dosing for 14 days, induces dose dependent anti-tumor effects starting at 1 mg/kg with strong regression at 10, 30 and 100 mg/kg [1].
References on ASP3026:
[1]. Sadao Kuromitsu, et al. AACR 102nd Annual Meeting, 2011.

Solubility

in DMSO > 10 mM

Melting point

Boiling point

Density

Formula Weight:

Flash point

Storage conditions

Store at -20°C 2 years

Appearance:

White to off-white solid